{"transactions":[{"id":869973,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T12:16:31.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":160237,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":320473,"derivative":{"underlying":"Common Stock","underlying_shares":160237},"source":{"system":"sec-edgar","filing":"0001062822-26-000035","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000035/form4.xml","form_type":"4"}},{"id":869972,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T12:16:31.000Z","date":"2026-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":54881,"price":1.47,"value":80675.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto."}],"balance_after":105356,"source":{"system":"sec-edgar","filing":"0001062822-26-000035","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000035/form4.xml","form_type":"4"}},{"id":869971,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T12:16:31.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":160237,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":160237,"source":{"system":"sec-edgar","filing":"0001062822-26-000035","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000035/form4.xml","form_type":"4"}},{"id":901904,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-17T21:06:19.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":409020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":409020,"derivative":{"exercise_price":1.37,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":409020},"source":{"system":"sec-edgar","filing":"0001062822-26-000020","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000020/form4.xml","form_type":"4"}},{"id":901903,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-17T21:06:19.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":272680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":272680,"derivative":{"underlying":"Common Stock","underlying_shares":272680},"source":{"system":"sec-edgar","filing":"0001062822-26-000020","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000020/form4.xml","form_type":"4"}},{"id":1264738,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-18T21:17:54.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":480710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":480710,"derivative":{"underlying":"Common Stock","underlying_shares":480710},"source":{"system":"sec-edgar","filing":"0001127602-25-005212","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760225005212/form4.xml","form_type":"4"}},{"id":1264737,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:17:54.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":721070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":721070,"derivative":{"exercise_price":0.695,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":721070},"source":{"system":"sec-edgar","filing":"0001127602-25-005212","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760225005212/form4.xml","form_type":"4"}},{"id":1319006,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-02T21:09:40.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":230000,"derivative":{"exercise_price":0.7385,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001127602-25-000084","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760225000084/form4.xml","form_type":"4"}},{"id":1423161,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-26T17:42:38.000Z","date":"2024-08-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5080,"price":1.52,"value":7721.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Upon the consummation of the Merger, pursuant to the Merger Agreement, 5,080 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $7,722, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-092946","document":"tm2422466-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465924092946/tm2422466-10_4seq1.xml","form_type":"4"}},{"id":1423160,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-26T17:42:38.000Z","date":"2024-08-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"price":1.52,"value":22800.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Upon the consummation of the merger (the \"Merger\") pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the \"Company\"), Insud Pharma, S.L. (\"Insud\"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud (\"Merger Sub\"), 15,000 restricted stock units (\"Agile RSUs\") were cancelled and converted into the right to receive a cash payment of $1.52 (the \"Merger Consideration\") per Agile RSU, for an aggregate of $22,800, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person."}],"balance_after":5080,"source":{"system":"sec-edgar","filing":"0001104659-24-092946","document":"tm2422466-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465924092946/tm2422466-10_4seq1.xml","form_type":"4"}},{"id":1765102,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-10-04T16:45:13.000Z","date":"2023-10-03","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") which were granted as an inducement grant to a new hire on October 3, 2023. The RSUs will vest in four equal installments over four years with the first installment vesting on August 16, 2024 and with the RSUs being fully vested on August 16, 2027."}],"balance_after":20080,"source":{"system":"sec-edgar","filing":"0001104659-23-106855","document":"tm2327624-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465923106855/tm2327624-1_4seq1.xml","form_type":"4"}},{"id":2198823,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2022-08-01T17:00:42.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":89200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of these options vest on July 28, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":89200,"derivative":{"exercise_price":1.09,"expiration_date":"2032-07-28","underlying":"Common Stock","underlying_shares":89200},"source":{"system":"sec-edgar","filing":"0001104659-22-084760","document":"tm2222147-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1608536/000110465922084760/tm2222147-1_4seq1.xml","form_type":"4"}},{"id":2198822,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-01T17:00:42.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":60800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock as follows: (i) 20,266 shares on July 28, 2023, (ii) 20,267 shares on July 28, 2024 and (iii) 20,267 shares on July 28, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":145065,"source":{"system":"sec-edgar","filing":"0001104659-22-084760","document":"tm2222147-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1608536/000110465922084760/tm2222147-1_4seq1.xml","form_type":"4"}},{"id":2239883,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-06-07T17:02:59.000Z","date":"2022-06-03","kind":"tax_withholding","acquired":false,"shares":35284,"price":0.805,"value":28403.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 86,067 restricted stock units."}],"balance_after":84265,"source":{"system":"sec-edgar","filing":"0001104659-22-069009","document":"tm2217848-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1608536/000110465922069009/tm2217848-3_4seq1.xml","form_type":"4"}},{"id":2334849,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2022-03-14T17:02:26.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":185900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":185900,"derivative":{"exercise_price":1.82,"expiration_date":"2032-03-10","underlying":"Common Stock","underlying_shares":185900},"source":{"system":"sec-edgar","filing":"0001104659-22-033391","document":"tm229119-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1608536/000110465922033391/tm229119-3_4seq1.xml","form_type":"4"}},{"id":2334848,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-14T17:02:26.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":42900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 14,300 shares on March 10, 2023, (ii) 14,300 shares on March 10, 2024 and (iii) 14,300 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":119549,"source":{"system":"sec-edgar","filing":"0001104659-22-033391","document":"tm229119-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1608536/000110465922033391/tm229119-3_4seq1.xml","form_type":"4"}},{"id":2364335,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-01T17:01:54.000Z","date":"2022-02-25","kind":"tax_withholding","acquired":false,"shares":14817,"price":1.74,"value":25781.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 32,167 restricted stock units."}],"balance_after":76649,"source":{"system":"sec-edgar","filing":"0001104659-22-028760","document":"tm227953-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1608536/000110465922028760/tm227953-2_4seq1.xml","form_type":"4"}},{"id":2587707,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-27T17:01:25.000Z","date":"2021-08-25","kind":"tax_withholding","acquired":false,"shares":7534,"price":3.98,"value":29985.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 21,166 restricted stock units."}],"balance_after":91466,"source":{"system":"sec-edgar","filing":"0001104659-21-110596","document":"tm2126037-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1608536/000110465921110596/tm2126037-2_4seq1.xml","form_type":"4"}},{"id":2825297,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2021-03-01T19:03:41.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":143000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":143000,"derivative":{"exercise_price":6,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":143000},"source":{"system":"sec-edgar","filing":"0001140361-21-006728","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1608536/000114036121006728/form4.xml","form_type":"4"}},{"id":2825296,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-01T19:03:41.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":63500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 21,166 shares on August 25, 2021, (ii) 21,167 shares on February 25, 2022 and (iii) 21,167 shares on August 25, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":99000,"source":{"system":"sec-edgar","filing":"0001140361-21-006728","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1608536/000114036121006728/form4.xml","form_type":"4"}},{"id":2825295,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-01T19:03:41.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 11,000 shares on February 25, 2022, (ii) 11,000 shares on February 25, 2023 and (iii) 11,000 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":35500,"source":{"system":"sec-edgar","filing":"0001140361-21-006728","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1608536/000114036121006728/form4.xml","form_type":"4"}},{"id":3193925,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2020-03-26T17:00:35.000Z","date":"2020-03-24","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of these options vest on March 24, 2021, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":55000,"derivative":{"exercise_price":35.5,"expiration_date":"2030-03-24","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001104659-20-038875","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1608536/000110465920038875/a4.xml","form_type":"4"}},{"id":3396458,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2019-10-07T19:15:59.000Z","date":"2019-10-07","kind":"grant","acquired":true,"shares":150824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of these options vest on October 2, 2020, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":150824,"derivative":{"exercise_price":15,"expiration_date":"2029-10-02","underlying":"Common Stock","underlying_shares":150824},"source":{"system":"sec-edgar","filing":"0001140361-19-018071","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1608536/000114036119018071/form4.xml","form_type":"4"}},{"id":3396457,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"officer":true,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-10-07T19:15:59.000Z","date":"2019-10-07","kind":"purchase","acquired":true,"shares":2500,"price":15,"value":37500.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001140361-19-018071","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1608536/000114036119018071/form4.xml","form_type":"4"}},{"id":3681118,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-01-31T17:30:42.000Z","date":"2019-01-29","kind":"grant","acquired":true,"shares":38500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 29, 2019.  25% of the shares subject to the stock option vest on January 29, 2020, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 29, 2023."}],"balance_after":38500,"derivative":{"exercise_price":2.5,"expiration_date":"2029-01-28","underlying":"Common Stock","underlying_shares":38500},"source":{"system":"sec-edgar","filing":"0001104659-19-004818","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465919004818/a4.xml","form_type":"4"}},{"id":3681117,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-01-31T17:30:42.000Z","date":"2019-01-29","kind":"grant","acquired":true,"shares":172600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 29, 2019.  25% of the shares subject to the stock option vest on January 29, 2020, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 29, 2023."}],"balance_after":172600,"derivative":{"exercise_price":0.84,"expiration_date":"2029-01-28","underlying":"Common Stock","underlying_shares":172600},"source":{"system":"sec-edgar","filing":"0001104659-19-004818","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465919004818/a4.xml","form_type":"4"}},{"id":3685246,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-01-28T17:30:51.000Z","date":"2019-01-25","kind":"exercise","acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On January 25, 2017, the reporting person was granted 35,000 restricted stock units that vest as follows: 17,500 units vested and were delivered on January 25, 2018, and 17,500 units vested and were delivered on January 25, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On January 25, 2017, the reporting person was granted 35,000 restricted stock units that vest as follows: 17,500 units vested and were delivered on January 25, 2018, and 17,500 units vested and were delivered on January 25, 2019."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001104659-19-003715","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465919003715/a4.xml","form_type":"4"}},{"id":3685245,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-01-28T17:30:51.000Z","date":"2019-01-24","kind":"exercise","acquired":false,"shares":16070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 24, 2018 the reporting person was granted 16,070 restricted stock units that fully vested and were delivered on January 24, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On January 24, 2018 the reporting person was granted 16,070 restricted stock units that fully vested and were delivered on January 24, 2019."}],"balance_after":17500,"derivative":{"underlying":"Common Stock","underlying_shares":16070},"source":{"system":"sec-edgar","filing":"0001104659-19-003715","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465919003715/a4.xml","form_type":"4"}},{"id":3685244,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-01-28T17:30:51.000Z","date":"2019-01-25","kind":"exercise","acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":48256,"source":{"system":"sec-edgar","filing":"0001104659-19-003715","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465919003715/a4.xml","form_type":"4"}},{"id":3685243,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-01-28T17:30:51.000Z","date":"2019-01-24","kind":"exercise","acquired":true,"shares":16070,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":30756,"source":{"system":"sec-edgar","filing":"0001104659-19-003715","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465919003715/a4.xml","form_type":"4"}},{"id":3885960,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-06-21T17:31:06.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 20, 2018.  25% of the shares subject to the stock option vested on the date of grant. The remaining shares vest in 3 equal 25% installments on December 31, 2018, June 30, 2019 and December 31, 2019."}],"balance_after":150000,"derivative":{"exercise_price":0.58,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001104659-18-041580","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465918041580/a4.xml","form_type":"4"}},{"id":4088011,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-01-26T17:16:18.000Z","date":"2018-01-25","kind":"exercise","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on January 25, 2017 and vest as follows: 17,500 units vested and were delivered on January 25, 2018, and 17,500 units will vest and be delivered on January 25, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on January 25, 2017 and vest as follows: 17,500 units vested and were delivered on January 25, 2018, and 17,500 units will vest and be delivered on January 25, 2019."}],"balance_after":33570,"derivative":{"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001104659-18-004318","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465918004318/a4.xml","form_type":"4"}},{"id":4088010,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-01-26T17:16:18.000Z","date":"2018-01-24","kind":"grant","acquired":true,"shares":16070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on January 24, 2018 and will be fully vested and delivered on January 24, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on January 24, 2018 and will be fully vested and delivered on January 24, 2019."}],"balance_after":51070,"derivative":{"underlying":"Common Stock","underlying_shares":16070},"source":{"system":"sec-edgar","filing":"0001104659-18-004318","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465918004318/a4.xml","form_type":"4"}},{"id":4088009,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Options (Right to Buy)","published_at":"2018-01-26T17:16:18.000Z","date":"2018-01-24","kind":"grant","acquired":true,"shares":107000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 24, 2018.  25% of the shares subject to the stock option vest on January 24, 2019, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 24, 2022."}],"balance_after":107000,"derivative":{"exercise_price":3.46,"expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":107000},"source":{"system":"sec-edgar","filing":"0001104659-18-004318","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465918004318/a4.xml","form_type":"4"}},{"id":4088008,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-01-26T17:16:18.000Z","date":"2018-01-25","kind":"tax_withholding","acquired":false,"shares":6753,"price":3.32,"value":22419.96,"ownership":{"direct":true},"balance_after":14686,"source":{"system":"sec-edgar","filing":"0001104659-18-004318","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465918004318/a4.xml","form_type":"4"}},{"id":4088007,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-01-26T17:16:18.000Z","date":"2018-01-25","kind":"exercise","acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":21439,"source":{"system":"sec-edgar","filing":"0001104659-18-004318","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465918004318/a4.xml","form_type":"4"}},{"id":4479015,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2017-01-27T16:33:38.000Z","date":"2017-01-25","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on January 25, 2017 and vest as follows: 17,500 units will vest and be delivered on January 25, 2018, and 17,500 units will vest and be delivered on January 25, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on January 25, 2017 and vest as follows: 17,500 units will vest and be delivered on January 25, 2018, and 17,500 units will vest and be delivered on January 25, 2019."}],"balance_after":35000,"derivative":{"underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-17-004568","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465917004568/a4.xml","form_type":"4"}},{"id":4479014,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":63541,"kind":"person","name":"Coiante Scott M","position":1,"cik":"0001608536","reported_name":"Coiante Scott M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-01-27T16:33:38.000Z","date":"2017-01-25","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 25, 2017.  25% of the shares subject to the stock option vest on January 25, 2018, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 25, 2021."}],"balance_after":100000,"derivative":{"exercise_price":2.26,"expiration_date":"2027-01-24","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-17-004568","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465917004568/a4.xml","form_type":"4"}}]}